See more : Halliburton Company (HAL.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Navamedic ASA (NAVA.OL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Navamedic ASA, a leading company in the Medical – Distribution industry within the Healthcare sector.
- Vornado Realty Trust (VNORP) Income Statement Analysis – Financial Results
- Helmerich & Payne, Inc. (0J4G.L) Income Statement Analysis – Financial Results
- Keikyu Corporation (9006.T) Income Statement Analysis – Financial Results
- Jyske Invest Aktier Lav Volatilitet KL (JYIALVKL.CO) Income Statement Analysis – Financial Results
- Juno Minerals Limited (JNO.AX) Income Statement Analysis – Financial Results
Navamedic ASA (NAVA.OL)
About Navamedic ASA
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, women's health, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 512.00M | 382.14M | 278.44M | 209.88M | 188.75M | 184.02M | 257.92M | 274.30M | 248.35M | 223.07M | 151.77M | 88.68M | 71.30M | 55.09M | 52.59M | 46.11M | 31.84M | 386.45K | 4.43M | 1.17M | 87.00K |
| Cost of Revenue | 312.94M | 218.62M | 166.70M | 139.54M | 131.15M | 122.64M | 187.65M | 204.26M | 187.45M | 168.81M | 104.45M | 51.17M | 42.03M | 32.99M | 31.96M | 25.32M | 10.67M | 330.06K | 2.08M | 685.54K | 29.11K |
| Gross Profit | 199.05M | 163.52M | 111.74M | 70.34M | 57.60M | 61.39M | 70.27M | 70.04M | 60.90M | 54.26M | 47.32M | 37.52M | 29.27M | 22.10M | 20.63M | 20.78M | 21.16M | 56.39K | 2.36M | 484.65K | 57.89K |
| Gross Profit Ratio | 38.88% | 42.79% | 40.13% | 33.51% | 30.52% | 33.36% | 27.25% | 25.53% | 24.52% | 24.32% | 31.18% | 42.30% | 41.06% | 40.12% | 39.23% | 45.08% | 66.48% | 14.59% | 53.17% | 41.42% | 66.54% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 10.78M | 9.66M | 10.28M | 13.54M | 527.51K | 389.08K | 395.00K | 179.00K | 132.00K | 105.00K | 72.00K | 118.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.37M | 802.02K |
| Selling & Marketing | 47.10M | 38.80M | 26.03M | 15.07M | 4.57M | 5.13M | 6.54M | 6.86M | 7.86M | 8.23M | 9.24M | 5.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 57.88M | 48.46M | 36.31M | 28.60M | 5.10M | 5.52M | 6.93M | 7.03M | 8.00M | 8.33M | 9.31M | 5.62M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.37M | 802.02K |
| Other Expenses | 117.59M | 70.62M | 63.98M | 46.66M | 62.59M | 14.01M | -2.62M | 4.05M | -403.95K | 38.76M | 35.86M | 36.02M | 39.18M | 37.23M | 30.63M | 22.08M | 26.07M | 11.18M | 7.93M | 3.51M | -447.60K |
| Operating Expenses | 175.47M | 119.08M | 100.29M | 75.26M | 67.69M | 65.96M | 80.85M | 84.60M | 64.72M | 47.09M | 45.17M | 41.65M | 39.18M | 37.23M | 30.63M | 22.08M | 26.07M | 11.18M | 7.93M | 4.88M | 354.42K |
| Cost & Expenses | 488.42M | 337.69M | 266.98M | 214.80M | 198.84M | 188.59M | 268.49M | 288.86M | 252.17M | 215.90M | 149.62M | 92.81M | 81.20M | 70.22M | 62.59M | 47.41M | 36.75M | 11.51M | 10.01M | 5.57M | 383.53K |
| Interest Income | 4.21M | 3.08M | 2.79M | 2.52M | 9.60K | 14.11K | 21.57K | 19.13K | 15.93K | 20.28K | 525.43K | 55.11K | 373.27K | 289.89K | 391.65K | 180.70K | 1.16M | 106.00 | 0.00 | 92.03K | 75.55K |
| Interest Expense | 14.34M | 612.00K | 2.50M | 2.71M | 1.78M | 1.14M | 2.08M | 1.01M | 393.92K | 459.27K | 601.29K | 492.99K | 934.39K | 592.70K | 2.31M | 2.08M | 516.96K | 0.00 | 0.00 | 63.87K | 47.32K |
| Depreciation & Amortization | 11.93M | 7.24M | 6.72M | 3.66M | 3.63M | 2.31M | 11.76M | 14.07M | 12.65M | 8.56M | 6.49M | 6.23M | 6.72M | 8.63M | 6.80M | 11.16M | 6.41M | 834.84K | 2.16M | 284.11K | 13.68K |
| EBITDA | 37.10M | 54.27M | 16.68M | -4.57M | -8.71M | 15.51M | -2.48M | 5.05M | 8.83M | 15.42M | 6.02M | 1.72M | -2.96M | -8.76M | -2.51M | 9.86M | 4.13M | -9.67M | -3.27M | -3.46M | -287.54K |
| EBITDA Ratio | 7.25% | 15.18% | 4.16% | -4.88% | -5.34% | 7.81% | 0.98% | 4.79% | 1.11% | 5.25% | 3.57% | 1.94% | -3.18% | -11.26% | -4.77% | 21.38% | 6.45% | -2,503.13% | -73.71% | -289.77% | -330.50% |
| Operating Income | 23.58M | 50.76M | 4.86M | -4.93M | -10.09M | -4.57M | -10.57M | -14.57M | -3.82M | 7.16M | 2.16M | -4.23M | -9.36M | -15.13M | -10.00M | -1.30M | -4.91M | -11.12M | -5.58M | -3.71M | -345.72K |
| Operating Income Ratio | 4.61% | 13.28% | 1.75% | -2.35% | -5.34% | -2.48% | -4.10% | -5.31% | -1.54% | 3.21% | 1.42% | -4.77% | -13.13% | -27.46% | -19.01% | -2.82% | -15.42% | -2,878.54% | -125.81% | -317.10% | -397.38% |
| Total Other Income/Expenses | -12.75M | -1.94M | -9.10M | -11.67M | -5.39M | -2.74M | -6.56M | 4.10M | -6.48M | -6.09M | -3.83M | -874.81K | -14.74K | -302.81K | -1.92M | -1.90M | 316.81K | 615.96K | 152.26K | -205.00 | -2.82K |
| Income Before Tax | 10.83M | 42.51M | 2.36M | -16.60M | -15.48M | 7.01M | -17.13M | -10.47M | -10.30M | 2.70M | -1.67M | -5.00M | -9.92M | -15.43M | -11.92M | -3.21M | -4.36M | -10.51M | -5.42M | -3.74M | -348.54K |
| Income Before Tax Ratio | 2.12% | 11.12% | 0.85% | -7.91% | -8.20% | 3.81% | -6.64% | -3.82% | -4.15% | 1.21% | -1.10% | -5.64% | -13.91% | -28.01% | -22.66% | -6.95% | -13.69% | -2,719.15% | -122.37% | -319.50% | -400.62% |
| Income Tax Expense | 7.53M | 13.07M | 1.74M | -136.00K | 820.47K | -273.00K | -1.59M | 191.84K | 632.05K | 1.39M | -401.37K | -1.75M | -2.76M | -4.24M | -8.38M | -1.17M | -1.15M | -2.94M | -556.77K | -1.54M | -135.91K |
| Net Income | 3.30M | 29.43M | 618.00K | -16.46M | -16.30M | 7.28M | -15.54M | -10.66M | -10.93M | 1.31M | -1.27M | -3.25M | -7.16M | -11.19M | 12.82M | -8.08M | -3.21M | -7.57M | -4.87M | 5.28M | 484.45K |
| Net Income Ratio | 0.65% | 7.70% | 0.22% | -7.84% | -8.63% | 3.96% | -6.03% | -3.89% | -4.40% | 0.59% | -0.84% | -3.67% | -10.04% | -20.31% | 24.37% | -17.52% | -10.09% | -1,959.38% | -109.81% | 451.51% | 556.84% |
| EPS | 0.19 | 1.75 | 0.04 | -1.14 | -1.39 | 0.67 | -1.43 | -1.04 | -1.24 | -0.08 | -0.15 | -0.40 | -0.95 | -1.48 | 1.70 | -1.07 | -0.51 | -1.33 | -1.09 | 1.18 | 0.11 |
| EPS Diluted | 0.19 | 1.73 | 0.04 | -1.14 | -1.39 | 0.67 | -1.43 | -1.04 | -1.24 | -0.08 | -0.15 | -0.39 | -0.91 | -1.48 | 1.67 | -1.07 | -0.51 | -1.33 | -1.09 | 1.18 | 0.11 |
| Weighted Avg Shares Out | 17.27M | 16.81M | 16.30M | 14.46M | 11.72M | 10.88M | 10.88M | 10.29M | 8.79M | 8.57M | 8.52M | 8.18M | 7.55M | 7.55M | 7.55M | 7.55M | 6.34M | 5.69M | 4.47M | 4.47M | 4.47M |
| Weighted Avg Shares Out (Dil) | 17.61M | 17.02M | 16.30M | 14.46M | 11.72M | 10.88M | 10.88M | 10.29M | 8.79M | 8.57M | 8.60M | 8.38M | 7.85M | 7.55M | 7.65M | 7.55M | 6.34M | 5.69M | 4.47M | 4.47M | 4.47M |
Source: https://incomestatements.info
Category: Stock Reports